Navigation Links
PCL Alverno Laboratories Launches Blood Test to Aid in the Early Detection of Lung Cancer
Date:3/19/2013

(PRWEB) March 19, 2013

PCL Alverno announced today that it has recently entered into an agreement with Oncimmune® USA LLC to offer EarlyCDT®-Lung to their extensive physician base in the Midwest. EarlyCDT-Lung is an innovative blood test that aids in the risk assessment and the early detection of lung cancer.

“Oncimmune is excited to add PCL ALVERNO as a partner to offer EarlyCDT-Lung test to their physicians,” said Greg Stanley, Chief Commercial Officer at Oncimmune USA. “We believe that through this relationship with PCL ALVERNO and our growing base of partners in the US, we can improve the outlook and well-being for countless individuals who are at increased risk for developing lung cancer.”

Lung cancer is the primary cause of cancer deaths amongst men and women in the United States, killing more people each year than breast, colon, prostate, liver, kidney and melanoma combined. 85% of newly diagnosed cases of lung cancer are found symptomatically and most often at late stages; the 5-year survival rate can be as low as 4% in later stage lung cancer. In 2012, over 226,000 new cases of lung cancer were diagnosed and over 160,000 perished from the disease.

The performance and clinical utility of EarlyCDT-Lung test is supported by 17 peer-reviewed publications, click here. The test has a high specificity (93%), seven times fewer false positives and seven times better positive predictive value (PPV) than CT. Additionally, the test offers >91% accuracy, when considering a population with 2% prevalence of lung cancer (20 lung cancers per thousand).

Currently, numerous leading academic institutions, as well as more than 2,000 physicians throughout the United States are offering the test. A prospective audit of clinical data from the first 1,600 patients tested by EarlyCDT-Lung validates its utility to detect early-stage lung cancer and its overall performance, click here. Additionally, the Scottish government is conducting a 10,000-patient randomized clinical trial to validate the economic benefit of the test in screening high-risk patients, click here.

Patient blood samples sent to PCL ALVERNO will be analyzed at Oncimmune’s CLIA-certified laboratory located in De Soto, Kansas.

About PCL ALVERNO

PCL Alverno is a full service, community based medical laboratory performing over 750 tests in both clinical and anatomic pathology.

PCL Alverno's innovative, state-of-the-art laboratory is the only free-standing, local reference lab in its service area. PCL Alverno offers the convenience and personal customer service of a local laboratory with the sophistication of a large reference laboratory.

Our team of onsite pathologists, along with our excellent staff, are committed to serve you. PCL Alverno's pathologists are part of the pathology practice of Pathology Consultants, Inc. PCL Alverno is located at 2434 Interstate Plaza Drive, Hammond, IN 46324. You can reach us at 800-937-5521

About Oncimmune

Oncimmune is a privately funded company located in Nottingham, UK with US headquarters and a CLIA laboratory located just outside of Kansas City. The company launched a proprietary platform technology for early cancer detection, called EarlyCDT®. The first commercially available test, EarlyCDT®-Lung, a blood test to aid in the early detection and risk assessment of lung cancer, was released in 2009. The EarlyCDT® platform technology measures autoantibodies (immuno-biomarkers) in blood that form early in carcinogenesis. When the body recognizes something as “non-self,” one of the ways it responds is for the immune system to produce large amounts of antibodies. The immune system does not normally produce antibodies against normal tissue proteins and therefore these immuno-biomarkers to cancer antigens provide high specificity for cancer.

Read the full story at http://www.prweb.com/releases/2013/3/prweb10525235.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. Interlinked and InterlinkedTV Announce Heart Test Laboratories Exclusive Interview From NEAA
2. ARUP Laboratories Introduces Blood Test to Aid in the Early Detection of Lung Cancer
3. TriMix Laboratories Announces New TriMix-gel Partnership with US Compounding
4. Glidewell Laboratories Discontinues Digital Treatment Planning and Guided Surgery Services for Implant Cases
5. Glidewell Laboratories Announces Customized Implant Component Stocking Inventory
6. IntegraGen launches ARISk test, a genetic screening tool for autism in high-risk children
7. Mayo Clinic launches whole genome breast cancer study
8. Original research papers on acute cardiovascular care: ESC launches EHJ-ACVC
9. UCLA launches first face transplantation program in western US
10. Georgia Tech launches HomeLab to help companies evaluate home health technologies
11. US Drug Watchdog Launches Now Calls Transvaginal Mesh A Disaster For 100,000's of US Women Recipients And Offers The Names and Contacts Of The Best Women Attorneys
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... ... June 26, 2016 , ... PawPaws brand pet supplements owned ... developed to enhance the health of felines. The formula is all-natural and is made ... in the PawPaws Cat Kidney Support Supplement Soft Chews are Astragalus Root ...
(Date:6/25/2016)... Austin, TX (PRWEB) , ... June 25, 2016 , ... ... Fellow of the American College of Mohs Surgery and to Dr. Russell Peckham for ... popular and highly effective treatment for skin cancer. The selective fellowship in Mohs Micrographic ...
(Date:6/25/2016)... , ... June 25, 2016 , ... As a lifelong ... Cum Laude and his M.D from the David Geffen School of Medicine at UCLA. ... to Los Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article published June ... with. The article goes on to state that individuals are now more comfortable seeking ... common operations such as calf and cheek reduction. The Los Angeles area medical group, ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Pulmonary ... Dallas that it will receive two significant new grants to support its work ... marked its 25th anniversary by recognizing patients, medical professionals and scientists for their ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... , June 24, 2016  American Respiratory Labs (ARL), a ... now able to perform sophisticated lung assessments in patients, homes, thanks ... Inc. Patients are no longer limited to having ... PRO ® , ARL patients like Jeanne R. of ... the comfort of her own home. ...
(Date:6/24/2016)... According to a new market ... Needles, Safety Pen Needles), Needle Length (4mm, 5mm, 6mm, ... of Purchase (Retail, Non-Retail) - Trends & Global Forecasts ... market for the forecast period of 2016 to 2021. ... by 2021 from USD 1.65 Billion in 2016, growing ...
(Date:6/24/2016)... Belgium , June 24, 2016 ... the appointment of Dr. Edward Futcher ... Non-Executive Director, effective June 23, 2016.Dr. Futcher was ... Nominations and Governance Committees.  As a non-executive member ... independent expertise and strategic counsel to VolitionRx in ...
Breaking Medicine Technology: